These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 15476662)

  • 1. Novel antitumor indenoindole derivatives targeting DNA and topoisomerase II.
    Bal C; Baldeyrou B; Moz F; Lansiaux A; Colson P; Kraus-Berthier L; Léonce S; Pierré A; Boussard MF; Rousseau A; Wierzbicki M; Bailly C
    Biochem Pharmacol; 2004 Nov; 68(10):1911-22. PubMed ID: 15476662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intoplicine (RP 60475) and its derivatives, a new class of antitumor agents inhibiting both topoisomerase I and II activities.
    Riou JF; Fossé P; Nguyen CH; Larsen AK; Bissery MC; Grondard L; Saucier JM; Bisagni E; Lavelle F
    Cancer Res; 1993 Dec; 53(24):5987-93. PubMed ID: 8261412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-activity relationships for substituted bis(acridine-4-carboxamides): a new class of anticancer agents.
    Gamage SA; Spicer JA; Atwell GJ; Finlay GJ; Baguley BC; Denny WA
    J Med Chem; 1999 Jul; 42(13):2383-93. PubMed ID: 10395479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel tetra-acridine derivatives as dual inhibitors of topoisomerase II and the human proteasome.
    Vispé S; Vandenberghe I; Robin M; Annereau JP; Créancier L; Pique V; Galy JP; Kruczynski A; Barret JM; Bailly C
    Biochem Pharmacol; 2007 Jun; 73(12):1863-72. PubMed ID: 17391647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological evaluation of omega-(dialkylamino)alkyl derivatives of 6H-indolo[2,3-b]quinoline--novel cytotoxic DNA topoisomerase II inhibitors.
    Godlewska J; Luniewski W; Zagrodzki B; Kaczmarek L; Bielawska-Pohl A; Dus D; Wietrzyk J; Opolski A; Siwko M; Jaromin A; Jakubiak A; Kozubek A; Peczyñska-Czoch W
    Anticancer Res; 2005; 25(4):2857-68. PubMed ID: 16080538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-activity studies with cytotoxic anthrapyrazoles.
    Begleiter A; Lin D; Larson KK; Lang J; Wu X; Cabral T; Taylor H; Guziec LJ; Kerr PD; Hasinoff BB; Guziec FS
    Oncol Rep; 2006 Jun; 15(6):1575-80. PubMed ID: 16685398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. F14512, a potent antitumor agent targeting topoisomerase II vectored into cancer cells via the polyamine transport system.
    Barret JM; Kruczynski A; Vispé S; Annereau JP; Brel V; Guminski Y; Delcros JG; Lansiaux A; Guilbaud N; Imbert T; Bailly C
    Cancer Res; 2008 Dec; 68(23):9845-53. PubMed ID: 19047165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
    Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel 4 beta-anilino-podophyllotoxin derivatives: design synthesis and biological evaluation as potent DNA-topoisomerase II poisons and anti-MDR agents.
    Hu C; Xu D; Du W; Qian S; Wang L; Lou J; He Q; Yang B; Hu Y
    Mol Biosyst; 2010 Feb; 6(2):410-20. PubMed ID: 20094661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Syntheses and biological activities (topoisomerase inhibition and antitumor and antimicrobial properties) of rebeccamycin analogues bearing modified sugar moieties and substituted on the imide nitrogen with a methyl group.
    Anizon F; Belin L; Moreau P; Sancelme M; Voldoire A; Prudhomme M; Ollier M; Sevère D; Riou JF; Bailly C; Fabbro D; Meyer T
    J Med Chem; 1997 Oct; 40(21):3456-65. PubMed ID: 9341921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pattern of antitumor activity of a novel camptothecin, ST1481, in a large panel of human tumor xenografts.
    Pratesi G; De Cesare M; Carenini N; Perego P; Righetti SC; Cucco C; Merlini L; Pisano C; Penco S; Carminati P; Vesci L; Zunino F
    Clin Cancer Res; 2002 Dec; 8(12):3904-9. PubMed ID: 12473606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor agents. 194. Synthesis and biological evaluations of 4-beta-mono-, -di-, and -trisubstituted aniline-4'-O-demethyl-podophyllotoxin and related compounds with improved pharmacological profiles.
    Zhu XK; Guan J; Tachibana Y; Bastow KF; Cho SJ; Cheng HH; Cheng YC; Gurwith M; Lee KH
    J Med Chem; 1999 Jul; 42(13):2441-6. PubMed ID: 10395485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Linker length in podophyllotoxin-acridine conjugates determines potency in vivo and in vitro as well as specificity against MDR cell lines.
    Rothenborg-Jensen L; Hansen HF; Wessel I; Nitiss JL; Schmidt G; Jensen PB; Sehested M; Jensen LH
    Anticancer Drug Des; 2001 Dec; 16(6):305-15. PubMed ID: 12375883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Substitution at the F-ring N-imide of the indolocarbazole antitumor drug NB-506 increases the cytotoxicity, DNA binding, and topoisomerase I inhibition activities.
    Bailly C; Qu X; Chaires JB; Colson P; Houssier C; Ohkubo M; Nishimura S; Yoshinari T
    J Med Chem; 1999 Jul; 42(15):2927-35. PubMed ID: 10425102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and antiproliferative evaluation of certain indeno[1,2-c]quinoline derivatives. Part 2.
    Tseng CH; Tzeng CC; Yang CL; Lu PJ; Chen HL; Li HY; Chuang YC; Yang CN; Chen YL
    J Med Chem; 2010 Aug; 53(16):6164-79. PubMed ID: 20662543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of DNA topoisomerase II by imidazoacridinones, new antineoplastic agents with strong activity against solid tumors.
    Skladanowski A; Plisov SY; Konopa J; Larsen AK
    Mol Pharmacol; 1996 May; 49(5):772-80. PubMed ID: 8622625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis, cytotoxicity, DNA interaction, and topoisomerase II inhibition properties of novel indeno[2,1-c]quinolin-7-one and indeno[1,2-c]isoquinolin-5,11-dione derivatives.
    Ryckebusch A; Garcin D; Lansiaux A; Goossens JF; Baldeyrou B; Houssin R; Bailly C; Hénichart JP
    J Med Chem; 2008 Jun; 51(12):3617-29. PubMed ID: 18507368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials.
    Poddevin B; Riou JF; Lavelle F; Pommier Y
    Mol Pharmacol; 1993 Oct; 44(4):767-74. PubMed ID: 8232227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topoisomerase II DNA cleavage stimulation, DNA binding activity, cytotoxicity, and physico-chemical properties of 2-aza- and 2-aza-oxide-anthracenedione derivatives.
    De Isabella P; Palumbo M; Sissi C; Capranico G; Carenini N; Menta E; Oliva A; Spinelli S; Krapcho AP; Giuliani FC
    Mol Pharmacol; 1995 Jul; 48(1):30-8. PubMed ID: 7623772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. WRC-213, an l-methionine-conjugated mitoxantrone derivative, displays anticancer activity with reduced cardiotoxicity and drug resistance: identification of topoisomerase II inhibition and apoptotic machinery in prostate cancers.
    Hsiao CJ; Li TK; Chan YL; Hsin LW; Liao CH; Lee CH; Lyu PC; Guh JH
    Biochem Pharmacol; 2008 Feb; 75(4):847-56. PubMed ID: 18035333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.